These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cell fusion: from hybridoma to dendritic cell-based vaccine. Gong J; Koido S; Calderwood SK Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954 [TBL] [Abstract][Full Text] [Related]
24. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. McIlroy D; Gregoire M Cancer Immunol Immunother; 2003 Oct; 52(10):583-91. PubMed ID: 12827310 [TBL] [Abstract][Full Text] [Related]
25. DNA vaccines for cancer too. Yu M; Finn OJ Cancer Immunol Immunother; 2006 Feb; 55(2):119-30. PubMed ID: 16032397 [No Abstract] [Full Text] [Related]
26. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects]. Rossowska J; Pajtasz-Piasecka E Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967 [TBL] [Abstract][Full Text] [Related]
27. Dendritic cell biology and cancer therapy. Whiteside TL; Odoux C Cancer Immunol Immunother; 2004 Mar; 53(3):240-8. PubMed ID: 14685779 [TBL] [Abstract][Full Text] [Related]
28. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. Breckpot K; Heirman C; Neyns B; Thielemans K J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193 [TBL] [Abstract][Full Text] [Related]
29. IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032 [TBL] [Abstract][Full Text] [Related]
30. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells]. Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759 [TBL] [Abstract][Full Text] [Related]
32. [Application of dendritic cells in clinical tumor therapy]. Li Y; Xian LJ Ai Zheng; 2002 Apr; 21(4):443-6. PubMed ID: 12452029 [TBL] [Abstract][Full Text] [Related]
33. The ongoing evolution of dendritic cell therapy. Sokoloff MH; Vogelzang N Cancer; 1999 Dec; 86(12):2593-6. PubMed ID: 10594853 [No Abstract] [Full Text] [Related]
34. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Banchereau J; Fay J; Pascual V; Palucka AK Novartis Found Symp; 2003; 252():226-35; discussion 235-8, 257-67. PubMed ID: 14609222 [TBL] [Abstract][Full Text] [Related]
35. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus]. Eymard JC; Gervais A; Jarcau R; Bernard J Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996 [TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Mossoba ME; Medin JA Expert Rev Vaccines; 2006 Oct; 5(5):717-32. PubMed ID: 17181444 [TBL] [Abstract][Full Text] [Related]
37. Dendritic cells in cancer immunotherapy. Vulink A; Radford KJ; Melief C; Hart DN Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410 [TBL] [Abstract][Full Text] [Related]
38. Current issues in delivering DCs for immunotherapy. Barratt-Boyes SM; Figdor CG Cytotherapy; 2004; 6(2):105-10. PubMed ID: 15203986 [TBL] [Abstract][Full Text] [Related]